Retatrutide: Mechanism of Action

Mecanismo de Acao

Retatrutide functions como um(a) simultaneous triple G protein-coupled agonista do receptor, activating the GIP receptor, the GLP-1 receptor, e o(a) glucagon receptor from a single peptide molecule. This "Triple G" mechanism integrates appetite supressao, insulinotropic effects, and aprimorou energy expenditure into one pharmacological agent.[4][10]

Receptor Binding Properties

Property	GIP Receptor (GIPR)	GLP-1 Receptor (GLP-1R)	Glucagon Receptor (GCGR)
Relative Potency (vs. endogenous ligand)	8.9× aquele(a) de native GIP	0.4× aquele(a) de native GLP-1	0.3× aquele(a) de native glucagon
EC50 (Human, In Vitro)	0.0643 nM	0.775 nM	5.79 nM
EC50 (Mouse)	0.191 nM	0.794 nM	2.32 nM
Design Profile	Highest potency — primary backbone origin	Attenuated — melhora GI tolerability	Attenuated — balanced by insulinotropic effects
Evidence	Coskun et al. (2022)[4]	Coskun et al. (2022)[4]	Coskun et al. (2022)[4]

Downstream Signaling Cascade

Step	Signaling Event	Molecular Detail
1. Receptor Binding	Retatrutide liga-se a GIPR, GLP-1R, and/or GCGR on target cell membranes	All three are Gs-coupled GPCRs[4]
2. G-Protein Coupling	Conformational change ativa Gs proteins	Stimulates adenylate cyclase[4]
3. cAMP Elevation	Adenylate cyclase converts ATP to cyclic AMP (cAMP)	cAMP acts as second messenger[11]
4. PKA Activation	Elevated cAMP ativa Protein Kinase A (PKA) and RAPGEF4 (Epac2)	Downstream effector ativacao[11]
5. Ion Channel Modulation	In β-cells: closure of KATP channels, opening of voltage-gated Ca2+ channels	Ca2+ influx desencadeia insulin granule exocytosis[11]
6. Gene Expression	Nuclear signaling promove insulin biosynthesis and β-proliferacao celular	Long-term metabolic adaptation[11]

Tissue-Level Effects by Organ System

Tissue / Organ	Effect	Primary Receptor(s)	Evidence
Pancreas (β-cells)	Glucose-dependent secrecao de insulinum(a) potenteiated	GLP-1R, GIPR	Coskun et al. (2022)[4]
Pancreas (α-cells)	Suppressed glucagon secretion during hiperglicemia (net glycemic improvement apesar de GCGR ativacao)	GLP-1R (suppressive), GCGR (counterbalanced)	Rosenstock et al. (2023)[2]
Liver	Increased mitochondrial fatty acid oxidation; reduziu hepatico(a) lipogenesis; up to 86% relative liver fat reduction	GCGR (primary), GLP-1R	Sanyal et al. (2024)[3]
Adipose Tissue	Increased energy expenditure; promoveu lipolysis in white tecido adiposo; melhorou lipid-buffering capacity	GCGR (lipolysis/EE), GIPR (lipid buffering)	Katsi et al. (2025)[10]
Central Nervous System	Hypothalamic appetite supressao and aprimorou satiety signaling	GLP-1R, GIPR	Abdul-Rahman et al. (2024)[11]
GI Tract	Delayed gastric emptying (atenua with cronico(a) dosing)	GLP-1R	Urva et al. (2023)[17]
Kidney	Potential renoprotective effects: reduziu albuminuria, melhorou renal hemodynamics over time	GLP-1R, indireto(a) (visceral fat reduction)	Heerspink et al. (2025)[7]

Comparison with Related Compounds

Caracteristica	Retatrutide (Triple Agonist)	Tirzepatide (Dual Agonist)	Semaglutide (Mono Agonist)
Receptor Targets	GLP-1, GIP, Glucagon	GLP-1, GIP	GLP-1 only
Glucagon Activity	Yes — aumenta energy expenditure & lipid oxidation	No	No
Primary Weight-Loss Mechanism	Appetite supressao + aumentou energy expenditure	Appetite supressao + metabolic regulacao	Appetite supressao
Weight Loss (Phase 2, 48 wks)	Up to 24.2%[1]	~11–12%	~15–17% (Phase 3, 68 wks)
Weight Loss (Phase 3)	Up to 28.7% at 68 wks[5]	~20–22% (Phase 3)	~15–17% (Phase 3)
Liver Fat Reduction (MASLD)	>85% resolution of steatosis[3]	Significant reduction	Significant reduction

The addition of glucagon receptor agonism e o(a) critico(a) pharmacological differentiator. While glucagon would normally raise glicose sanguinea via hepatico(a) glycogenolysis, the strong insulinotropic effects of GIP and GLP-1 receptor ativacao "buffer" este efeito, allowing the metabolic benefits of glucagon signaling — aumentou energy expenditure, aprimorou lipolysis, and hepatico(a) fat oxidation — to be safely harnessed sem worsening hiperglicemia.[4][10]